Wegovy is indicated for people ages 12 years and older who have: A BMI of 30 kg/m 2 or higher A BMI of 27 kg/m 2 to 29.9 kg/m 2 and at least one weight-related comorbidity , such as high blood pressure, type 2 diabetes, or obstructive sleep apnea Wegovy is also indicated to reduce the risk of major cardiovascular events , such as heart attack or stroke, in people who have obesity or overweight
Mounjaro is FDA-approved for type 2 diabetes
Semaglutide may also upregulate transcriptional responses to oxidative stress, which decrease with ageing, owing to the declining function of the stress-responsive NRF2 [194]
There is currently no proven, safe workaround.
Glutathione nasal spray should not be used as a substitute for medical treatment or advice
Which Therapy Is Best for Visceral Fat